Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBITDA (2016 - 2025)

Historic EBITDA for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.4 million.

  • Enanta Pharmaceuticals' EBITDA rose 3841.36% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$85.3 million, marking a year-over-year increase of 2986.42%. This contributed to the annual value of -$85.3 million for FY2025, which is 2986.42% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' EBITDA is -$18.4 million, which was up 3841.36% from -$18.9 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBITDA peaked at -$18.4 million during Q3 2025, and registered a low of -$39.5 million during Q1 2023.
  • For the 5-year period, Enanta Pharmaceuticals' EBITDA averaged around -$29.8 million, with its median value being -$30.4 million (2021).
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 15010.53% in 2021, then soared by 3841.36% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' EBITDA stood at -$30.4 million in 2021, then grew by 1.3% to -$30.0 million in 2022, then decreased by 16.24% to -$34.9 million in 2023, then soared by 32.51% to -$23.5 million in 2024, then grew by 21.9% to -$18.4 million in 2025.
  • Its EBITDA was -$18.4 million in Q3 2025, compared to -$18.9 million in Q2 2025 and -$24.5 million in Q1 2025.